Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김규보 | * |
dc.date.accessioned | 2018-11-21T16:30:23Z | - |
dc.date.available | 2018-11-21T16:30:23Z | - |
dc.date.issued | 2018 | * |
dc.identifier.issn | 0748-7983 | * |
dc.identifier.other | OAK-22363 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/246729 | - |
dc.description.abstract | Purpose: To evaluate the prognostic value of matrix metalloproteinase-9 (MMP-9) in patients with extrahepatic bile duct (EHBD) cancer undergoing surgical resection and adjuvant radiotherapy. Methods: Between January 2000 and August 2006, patients who underwent complete resection followed by adjuvant radiotherapy for EHBD cancer were enrolled in this study. The expression of MMP-9 was assessed with immunohistochemical staining. The prognostic values of the MMP-9 expression and other clinicopathologic factors were evaluated in univariate and multivariate analyses. Results: Sixty-six patients were included in this study. All received radiotherapy with a median dose of 40 Gy (range, 40–56), and 61 patients received concomitant fluoropyrimidine chemotherapy. MMP-9 was highly expressed in 33 patients (50.0%). MMP-9 expression was significantly associated with locoregional recurrence-free survival (LRRFS) and overall survival (OS) but not with distant metastasis-free survival (DMFS). The 5-year LRRFS and OS rates were 50.8% versus 86.5% (p =.0281), and 23.3% versus 68.1% (p =.0087) in patients with low and high expression of MMP-9, respectively. Among the clinicopathologic factors, tumor location was associated with DMFS and OS (p =.0292 and.0003, respectively). Nodal stage and histologic differentiation showed significant association with DMFS (p =.0277 and.0060, respectively). Based on multivariate analysis for OS, tumor location was the only significant prognostic factor (p =.0021), while MMP-9 expression showed marginal significance (p =.0633). Conclusion: MMP-9 expression is a useful prognostic factor for predicting LRRFS and OS in patients with EHBD cancer after surgical resection and adjuvant radiotherapy. © 2018 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology | * |
dc.language | English | * |
dc.publisher | W.B. Saunders Ltd | * |
dc.subject | Adjuvant radiotherapy | * |
dc.subject | Extrahepatic bile duct cancer | * |
dc.subject | Matrix metalloproteinase-9 | * |
dc.subject | Prognosis | * |
dc.title | High expression of MMP-9 is associated with better prognosis in extrahepatic bile duct cancer patients | * |
dc.type | Article | * |
dc.relation.issue | 5 | * |
dc.relation.volume | 44 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 638 | * |
dc.relation.lastpage | 643 | * |
dc.relation.journaltitle | European Journal of Surgical Oncology | * |
dc.identifier.doi | 10.1016/j.ejso.2018.01.012 | * |
dc.identifier.wosid | WOS:000433399800014 | * |
dc.identifier.scopusid | 2-s2.0-85044500993 | * |
dc.author.google | Park Y. | * |
dc.author.google | Kim K. | * |
dc.author.google | Paik J.H. | * |
dc.author.google | Chie E.K. | * |
dc.author.google | Jang J.-Y. | * |
dc.author.google | Kim S.W. | * |
dc.author.google | Oh D.-Y. | * |
dc.contributor.scopusid | 김규보(8213302900) | * |
dc.date.modifydate | 20240222162403 | * |